{"product_id":"africa-ivd-market-by-product-solution-technology-immunoassay-point-of-care-molecular-diagnostics-coagulation-application-infectious-diseases-diabetes-oncology-diagnostic-approach-lab-otc-poc-end-user-forecast-to-2030","title":"Africa IVD Market by Product \u0026 Solution, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), End User - Forecast to 2030","description":"\u003cp\u003eAfrica IVD Market by Product \u0026amp; Solution, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), End User - Forecast to 2030\u003cbr\u003e\nAfrica In Vitro Diagnostics Market by Product \u0026amp; Solution, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), End User — Forecast to 2030\u003c\/p\u003e\n\n\u003cp\u003eThe Africa IVD market is expected to grow at a CAGR of 2.8% from 2023 to 2030 to reach $1.49 billion by 2030.\u003c\/p\u003e\n\n\u003cp\u003eAfter a comprehensive secondary and primary research study and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the Africa IVD market.\u003c\/p\u003e\n\n\u003cp\u003eThe high prevalence of infectious diseases, the rising burden of chronic diseases, the rising initiatives to support the healthcare sector, and the growing awareness about the importance of early disease diagnosis are the major drivers for the Africa IVD market. However, poor healthcare facilities and infrastructure in African countries are the major challenges to the market’s growth.\u003c\/p\u003e\n\n\u003cp\u003eBased on product category, in 2023, the reagents \u0026amp; kits segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the frequent use of assays \u0026amp; kits in the detection of various chronic diseases coupled with the high burden of infectious diseases in African countries.\u003c\/p\u003e\n\n\u003cp\u003eBased on technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to its advantages such as high sensitivity and accuracy, high throughput capability, and the rising prevalence of infectious diseases.\u003c\/p\u003e\n\n\u003cp\u003eBased on application, in 2023, the infectious diseases segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is primarily attributed to the high prevalence of infectious diseases such as COVID-19, dengue, HIV, and Chagas disease in the region and the rising initiatives to boost testing capabilities.\u003c\/p\u003e\n\n\u003cp\u003eBased on diagnostic approach, in 2023, the lab testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the availability of several IVD tests and the higher accuracy offered by laboratory testing.\u003c\/p\u003e\n\n\u003cp\u003eBased on end user, in 2023, the hospitals \u0026amp; clinics segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the high demand for IVD diagnostics and the higher preference for hospitals as the primary center of care.\u003c\/p\u003e\n\n\u003cp\u003eBased on geography, in 2023, South Africa is expected to account for the largest share of this market. The major share of this region is mainly attributed to the high burden of diseases, the rising geriatric population, the increasing initiatives to promote diagnostic testing, and continuous efforts to develop healthcare infrastructure and promote awareness.\u003c\/p\u003e\n\n\u003cp\u003eThe key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).\u003c\/p\u003e\n\n\u003cp\u003eScope of the Report\u003c\/p\u003e\n\n\u003cp\u003eAfrica IVD Market Assessment–by Product Category\u003c\/p\u003e\n\n\u003cp\u003eReagents \u0026amp; Kits\u003cbr\u003e\nInstruments\u003cbr\u003e\nSoftware \u0026amp; Services\u003c\/p\u003e\n\n\u003cp\u003eAfrica IVD Market Assessment–by Technology\u003c\/p\u003e\n\n\u003cp\u003eMolecular Diagnostics\u003cbr\u003e\nPoint-of-care Diagnostics\u003cbr\u003e\nImmunoassay\/Immunochemistry\u003cbr\u003e\nBiochemistry\/Clinical Chemistry\u003cbr\u003e\nWhole Blood Glucose Monitoring\u003cbr\u003e\nHematology\u003cbr\u003e\nMicrobiology\u003cbr\u003e\nCoagulation \u0026amp; Hemostasis\u003cbr\u003e\nOther IVD Technologies\u003c\/p\u003e\n\n\u003cp\u003eNote: Other technologies include urinalysis, hybridization, and loop-mediated amplification.\u003c\/p\u003e\n\n\u003cp\u003eAfrica IVD Market Assessment–by Application\u003c\/p\u003e\n\n\u003cp\u003eInfectious Diseases\u003cbr\u003e\nOncology\u003cbr\u003e\nDiabetes\u003cbr\u003e\nCardiology\u003cbr\u003e\nNephrology\u003cbr\u003e\nAutoimmune Disorders\u003cbr\u003e\nOther Applications\u003c\/p\u003e\n\n\u003cp\u003eNote: Other applications include toxicology, gastroenterology, neonatal, genetic, and neurological disorders.\u003c\/p\u003e\n\n\u003cp\u003eAfrica IVD Market Assessment–by Diagnostic Approach\u003c\/p\u003e\n\n\u003cp\u003eLab Testing\u003cbr\u003e\nPoint-of-care Testing\u003cbr\u003e\nOTC\/Self-testing\u003c\/p\u003e\n\n\u003cp\u003eAfrica IVD Market Assessment–by End User\u003c\/p\u003e\n\n\u003cp\u003eHospitals \u0026amp; Clinics\u003cbr\u003e\nDiagnostic Laboratories\u003cbr\u003e\nHome Care\u003cbr\u003e\nOther End Users\u003c\/p\u003e\n\n\u003cp\u003eNote: Other end users include long-term care facilities, academic \u0026amp; research institutes, ambulatory care centers, and transfusion laboratories.\u003c\/p\u003e\n\n\u003cp\u003eAfrica IVD Market Assessment–by Country\u003c\/p\u003e\n\n\u003cp\u003eSouth Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nAlgeria\u003cbr\u003e\nNigeria\u003cbr\u003e\nMorocco\u003cbr\u003e\nKenya\u003cbr\u003e\nTunisia\u003cbr\u003e\nTanzania\u003cbr\u003e\nRest of Africa\u003c\/p\u003e \n\n\u003cp\u003eAfrica In Vitro Diagnostics Market  - Global Opportunity Analysis and Industry Forecast (2023–2030)  - Report SummaryReport MetricsDetailsYears Considered2021 - 2030Base Year2022Forecast Period2023-2030Page Count174Units ReferencedValue (USD Million)Segments\/Key TopicsMarket by Product Category, Technology, Application, Diagnostic Approach, and End UserRegions CoveredSouth Africa, Egypt, Algeria, Nigeria, Morocco, Kenya, Tunisia, Tanzania, and Rest of AfricaKey Companies MentionedAbbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).\u003c\/p\u003e\n\n\u003cp\u003eFAQs About the Report\u003c\/p\u003e\n\n\u003cp\u003eWhat is the focus of the Africa IVD market report?\u003c\/p\u003e\n\n\u003cp\u003eThe Africa IVD market report covers the market size \u0026amp; forecasts of various IVD products (reagents \u0026amp; kits, instruments, and software \u0026amp; services) offered by key market players based on various technologies such as immunoassay\/immunochemistry, whole blood glucose monitoring, molecular diagnostics, point-of-care diagnostics, biochemistry\/clinical chemistry, microbiology, hematology, coagulation \u0026amp; hemostasis, and other IVD technologies.\u003c\/p\u003e\n\n\u003cp\u003eThese IVD products are used for various applications, including infectious diseases, diabetes, oncology, cardiology, nephrology, autoimmune diseases, and other applications. The Africa IVD market study covers various IVD products used for lab testing, OTC\/self-testing, and point-of-care testing in diagnostic laboratories, hospitals \u0026amp; clinics, home healthcare, and other end users.\u003c\/p\u003e\n\n\u003cp\u003eWhat is the revenue generated from IVD products across Africa? At what rate is their demand expected to grow for the next 5–7 years?\u003c\/p\u003e\n\n\u003cp\u003eThe Africa IVD market is projected to reach $1.49 billion by 2030, at a CAGR of 2.8% during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eWhich product category is estimated to hold the major share of the market?\u003c\/p\u003e\n\n\u003cp\u003eBased on product category, in 2023, the reagents \u0026amp; kits segment is expected to account for the largest share of the Africa IVD market.\u003c\/p\u003e\n\n\u003cp\u003eWhich technology segment is estimated to hold the major share of the market?\u003c\/p\u003e\n\n\u003cp\u003eBased on technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the Africa IVD market.\u003c\/p\u003e\n\n\u003cp\u003eWhich application segment is projected to create more traction in the Africa IVD market?\u003c\/p\u003e\n\n\u003cp\u003eBased on application, the cardiology segment is slated to register the fastest growth rate during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eWhich end user segment is estimated to hold the major share of the market?\u003c\/p\u003e\n\n\u003cp\u003eBased on end user, in 2023, the hospitals \u0026amp; clinics testing segment is expected to account for the largest share of the Africa IVD market.\u003c\/p\u003e\n\n\u003cp\u003eWhat are the key factors supporting the growth of this market?\u003c\/p\u003e\n\n\u003cp\u003eThe high prevalence of infectious diseases, the rising burden of chronic diseases, the increasing initiatives to support the healthcare sector, and the growing awareness about the importance of early disease diagnosis are the key factors driving the growth of the Africa IVD market.\u003c\/p\u003e\n\n\u003cp\u003eWho are the major players operating in the Africa IVD Market?\u003c\/p\u003e\n\n\u003cp\u003eThe key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"July, 2023 \/ - \/ MCW16237454","offer_id":47652469571890,"sku":null,"price":9600.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/africa-ivd-market-by-product-solution-technology-immunoassay-point-of-care-molecular-diagnostics-coagulation-application-infectious-diseases-diabetes-oncology-diagnostic-approach-lab-otc-poc-end-user-forecast-to-2030","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}